Datapoint: Incyte Scores Merkel Cell Carcinoma Nod for Zynyz

The FDA last week approved Incyte Corp.’s Zynyz for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC), a rare form of skin cancer. The PD-1 inhibitor will join oncology heavyweights in MCC market basket — Merck’s Keytruda and Bristol Myers Squibb’s Opdivo. Under the medial benefit, Opdivo is currently the most advantaged MCC therapy, holding covered or better status for 89% of all insured lives. Keytruda follows closely behind at 88%.

SOURCE: MMIT Analytics, as of 3/27/23

0 Comments
© 2025 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 17

Datapoint: Michigan Awards Contracts for New Duals Program

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 16

Datapoint: CMS Releases 2025 Star Ratings

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 15

Datapoint: Pfizer Scores Another Hemophilia Nod

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today